- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
IX1
GER
Week ended 07 Aug 2026
Weekly Investor Report
IDEXX Laboratories, Inc. · Healthcare · Diagnostics & Research
Latest close
514.8 EUR
1.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 44.3% of its 52-week range. The latest completed week returned 1.1%, after a 7.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 56/100.
Setup score
49
out of 100
Latest Close
514.8 EUR
7 Aug 2026
1W Return
1.1%
latest completed week
4W Return
7.2%
short-term follow-through
12W Return
2.8%
quarterly tape
Trend Breadth
38.5%
20 of 52 weeks active
Volume Ratio
2.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Next-week expectancy is negative at 28.40% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.1%
Latest completed week; four-week move 7.2%.
Indicator stack
21/69
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 28.40%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
56/100
16 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.4% below the Trend Line and sits at 44.3% of its 52-week range. The latest completed week returned 1.1%, after a 7.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
23 Jan
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1812-week average 0.26
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 7.2% over four weeks, 2.8% over 12 weeks, and 29.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year20
Trend breadth38.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.34Latest activity-pressure read.
Pressure change156.4%Four-week change in activity pressure.
Leadership-4.82Latest relative-leadership reading.
RS change14.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength35/100Blend of value, momentum, and quality. Underlying universe rank 66; rank 1 is best.
Value4/100Relative valuation strength. Underlying universe rank 97; rank 1 is best.
Quality98/100Profitability and accounting quality. Underlying universe rank 3; rank 1 is best.
Momentum72/100Medium-term price momentum. Underlying universe rank 29; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 37.0x Price divided by trailing earnings.
- Price / sales
- 9.1x Market value relative to trailing revenue.
- EV / EBITDA
- 26.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 62.1% Gross profit retained from each unit of revenue.
- Operating margin
- 31.6% Operating profit retained from revenue.
- Free-cash-flow margin
- 24.0% Free cash flow generated from revenue.
- Return on invested capital
- 42.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 10.4% Latest one-year revenue growth.
- EPS growth
- 22.2% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 30.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 8/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 2.6% Net share repurchases relative to market value.
- Shareholder yield
- 2.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 16 relevant articles.
3 positive · 13 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-22.4%Distance below the 52-week high.
13-week volatility2.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
23 Jan
20 Feb
20 Mar
17 Apr
15 May
12 Jun
7 Aug
Weeks higher11 of 2611 weeks finished lower.
Best week+6.5%Week of 31 Jul.
Worst week-11.1%Week of 13 Mar.
Latest week+1.1%Week of 7 Aug.
Shape of recent returns
Strong gains1
Modest gains10
Flat weeks4
Modest losses7
Sharp losses4
Recent vol2.5%13-week weekly-return volatility.
Base vol7.9%52-week weekly-return volatility.
Up/down split17/16Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank21 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Diagnostics & Research
4-week rank2 / 6
Group average1.9%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD100.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape44/100
Trend, activity pressure, participation, and risk combine to a 44/100 tape read.
Indicator analysis20/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 3/12.
Activity pressure 0.18; No reversal markers Next-Week ExpectancyNegative 28.40%Next-week expectancy is negative with a 28.40% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors51/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 17; Small Cap Core rank 97 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment56/100Weighted news tone is neutral across 16 relevant articles.
IDEXX Laboratories Inc (IDXX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 514.8 EUR | 1.1% | 522.0 EUR | 456.2 EUR | 0.34 | -4.82 | 32 | Off |
| 31 Jul 2026 | 509.0 EUR | 6.5% | 524.9 EUR | 456.0 EUR | 0.08 | -3.06 | 1 | Off |
| 24 Jul 2026 | 478.1 EUR | -3.0% | 527.8 EUR | 455.9 EUR | -0.19 | -6.72 | 91 | Off |
| 17 Jul 2026 | 493.0 EUR | 2.6% | 533.2 EUR | 455.7 EUR | -0.37 | -2.55 | 23 | Off |
| 10 Jul 2026 | 480.3 EUR | -1.8% | 538.4 EUR | 455.5 EUR | -0.61 | -5.66 | 36 | Off |
| 12 Jun 2026 | 488.9 EUR | 0.3% | 543.2 EUR | 455.3 EUR | -0.80 | -2.09 | 0 | Off |
| 5 Jun 2026 | 487.4 EUR | 0.5% | 546.9 EUR | 454.9 EUR | -0.84 | -2.60 | 19 | Off |
| 29 May 2026 | 485.0 EUR | 1.4% | 550.9 EUR | 454.5 EUR | -0.88 | -4.11 | 0 | Off |
| 22 May 2026 | 478.2 EUR | -4.5% | 548.0 EUR | 454.2 EUR | -0.96 | -4.38 | 1 | Off |
| 15 May 2026 | 500.8 EUR | 0.0% | 545.2 EUR | 453.9 EUR | -1.01 | 4.31 | 0 | Off |
| 8 May 2026 | 500.8 EUR | 0.0% | 541.8 EUR | 453.6 EUR | -1.11 | 3.06 | 0 | Off |
| 1 May 2026 | 500.8 EUR | 0.0% | 538.3 EUR | 453.3 EUR | -1.14 | 3.62 | 0 | Off |
| 24 Apr 2026 | 500.8 EUR | 0.0% | 534.8 EUR | 452.9 EUR | -0.98 | 4.67 | 0 | Off |
| 17 Apr 2026 | 500.8 EUR | 2.7% | 531.4 EUR | 452.6 EUR | -0.93 | 2.53 | 13 | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.